Search Results - subject:"Amiodarone"

Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal

McKenna, Claire; Maund, Emma; Sarowar, Muhammad; Fox, David - In: PharmacoEconomics 30 (2012) 1, pp. 35-46

with a broader set of trials examining the effectiveness of other AADs for AF: amiodarone, sotalol and class 1c agents … amiodarone as first-line AAD, with incremental cost-effectiveness ratios (ICERs) well below £20 000 per QALY gained. The ICER for …

Persistent link: https://www.econbiz.de/10010614373

Cost Comparisons of Pharmacological Strategies in Open-Heart Surgery

Reddy, Prabashni; Song, Jessica - In: PharmacoEconomics 21 (2003) 4, pp. 249-262

amiodarone is associated with a reduction in AF and was cost-neutral compared with placebo. Compared with placebo, prevention of …

Persistent link: https://www.econbiz.de/10005404885

Cost Effectiveness of Therapies for Atrial Fibrillation: A Review

Teng, Mark P.; Catherwood, Edward; Melby, Daniel P. - In: PharmacoEconomics 18 (2000) 4, pp. 317-333

Atrial fibrillation is the most common supraventricular tachyarrhythmia encountered in clinical practice, affecting over 5% of persons over the age of 65 years. A common pathophysiological mechanism for arrhythmia development is atrial distention and fibrosis induced by hypertension, coronary...

Persistent link: https://www.econbiz.de/10005404810